[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654876":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":11,"studyPopulation":11,"armGroups":36,"interventions":50,"overallOfficials":65,"centralContacts":69,"locations":78,"responsibleParty":99,"collaborators":11,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":11,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":11,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":11,"overallStatus":81,"whyStopped":11,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":11},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen",null,"Predose on Day 1 through 36 hours post dose",{"measure":14,"description":11,"timeFrame":12},"PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t (AUC0-tlast) of Acetaminophen",{"measure":16,"description":11,"timeFrame":12},"PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen",[18,21,23,25],{"measure":19,"description":11,"timeFrame":20},"PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC0-∞) of Tirzepatide","Predose on Day 1 through Day 29",{"measure":22,"description":11,"timeFrame":20},"PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t (AUC0-tlast) of Tirzepatide",{"measure":24,"description":11,"timeFrame":20},"PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide",{"measure":26,"description":11,"timeFrame":20},"PK: Time of Maximum Observed Drug Concentration (Tmax) of Tirzepatide",{"allocation":28,"interventionModel":29,"interventionModelDescription":11,"primaryPurpose":30,"observationalModel":11,"timePerspective":11,"maskingInfo":31},"RANDOMIZED","PARALLEL","BASIC_SCIENCE",{"masking":32,"maskingDescription":11,"whoMasked":33},"DOUBLE",[34,35],"PARTICIPANT","INVESTIGATOR",[37,44],{"label":38,"type":39,"description":40,"interventionNames":41},"Tirzepatide + Acetaminophen","EXPERIMENTAL","Participants will receive tirzepatide administered subcutaneously (SC) and acetaminophen administered orally.",[42,43],"Drug: Tirzepatide","Drug: Acetaminophen",{"label":45,"type":46,"description":47,"interventionNames":48},"Placebo + Acetaminophen","PLACEBO_COMPARATOR","Participants will receive placebo administered SC and acetaminophen administered orally.",[43,49],"Drug: Placebo",[51,58,62],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"DRUG","Tirzepatide","Administered SC.",[38],[57],"LY3298176",{"type":52,"name":59,"description":60,"armGroupLabels":61,"otherNames":11},"Acetaminophen","Administered orally.",[45,38],{"type":52,"name":63,"description":54,"armGroupLabels":64,"otherNames":11},"Placebo",[45],[66],{"name":67,"affiliation":5,"role":68},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[70,75],{"name":71,"role":72,"phone":73,"phoneExt":11,"email":74},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":76,"role":72,"phone":11,"phoneExt":11,"email":77},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[79],{"facility":80,"status":81,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"Clinical Pharmacology of Miami","RECRUITING","Miami","Florida","33172","United States","US",{"type":88,"coordinates":89},"Point",[90,91],-80.19366,25.77427,{"lat":91,"lon":90},[94,96],{"name":11,"role":72,"phone":95,"phoneExt":11,"email":11},"305-817-2900",{"name":97,"role":98,"phone":11,"phoneExt":11,"email":11},"Angel Lamas","PRINCIPAL_INVESTIGATOR",{"type":100,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100654876","phase-1-a-study-of-tirzepatide-ly3298176-in-participants-with-type-1-diabetes-mellitus-and-overweight-or-obesity-100654876",false,"NCT07803744","A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity","A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity","Inclusion Criteria:\n\n* Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening\n* Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg\u002Fm2) at screening\n* Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening\n\nExclusion Criteria:\n\n* Participants who have a known clinically significant gastric emptying abnormality\n* Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery\n* Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists","ALL","18 Years","70 Years",{"count":112,"type":113},18,"ESTIMATED","INTERVENTIONAL",[116],"PHASE1","The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.\n\nParticipation in this study will last about 8 weeks, including screening and follow-up.",[119,120,121],"Diabetes Mellitus, Type 1","Overweight","Obesity","2026-09-21",{"date":124,"type":125},"2026-09-23","ACTUAL",{"date":127,"type":125},"2026-09-11",{"date":129,"type":113},"2026-12",{"name":5,"class":6},1]